Please note: the 2013 as reported quarterly and year-to-date information is based on the predecessor information of MacDermid, Incorporated ("MacDermid") and does not reflect the purchase accounting effect of Platform's acquisition of MacDermid in October 2013. In order to perform a proper comparison of the P&L between 2013 and 2014, the Company has made certain adjustments to its reported numbers, as detailed in the financial tables included in this press release. The Company believes that this "as adjusted" format provides a more complete understanding of its operational results and a meaningful comparison of its performance between periods.

For the three months ended December 31, 2014:

Net sales for the quarter increased 47.7% to $273.6 million compared to $185.3 million in the fourth quarter of 2013. On an organic basis, MacDermid's net sales of $185.6 million were up slightly year-over-year despite facing a $5 million foreign exchange headwind as a result of the strengthening U.S. dollar.

Reported net loss increased to ($266.7) million, compared to ($200.1) million for the same period in 2013. MacDermid's net loss decreased to ($10.1) million, compared to ($205.2) million in the same period in 2013.

Reported diluted earnings per share was ($1.59).

Adjusted EBITDA for the quarter rose 47.6% to $65.7 million compared to $44.5 million from the year-prior period. Excluding the impact of the AgroSolutions segment, adjusted EBITDA increased by 11.7% to $49.7 million, including an adverse foreign exchange impact of approximately $1.4 million.

Adjusted EBITDA margin levels were 24.0% for both quarters in 2014 and 2013. Adjusted EBITDA margin for the MacDermid business was 26.7%, representing a record level.

Adjusted net income attributable to common shareholders rose to $27.8 million in this quarter from $22.0 million in the fourth quarter of 2013.

Adjusted diluted earnings per share were $0.14, compared to $0.11 per adjusted diluted earnings per share in the same period of 2013.

Adjusted recurring free cash flow of $67.8 million, or $0.35 per adjusted diluted share, was 63.4% higher for this fourth quarter 2014 compared to the $41.5 million, or $0.21 per adjusted diluted share, reported in the fourth quarter of 2013.

For the twelve months ended December 31, 2014:

Net sales for the full year 2014 rose 13.0% to $843.2 million compared to $746 million in 2013. On an organic basis, net sales from MacDermid rose 1.2% to $755.2 million.

Reported net loss increased to ($262.7) million, compared to a loss of ($203.5) million in 2013. MacDermid reported net income of $0.3 million, compared to a net loss of ($203.5) million in 2013.

Adjusted EBITDA in 2014 reached $212.2 million, up 17.8%, compared to $180.1 million in 2013. The MacDermid business contributed $196.2 million, up 8.9% compared to last year.

Adjusted EBITDA margin levels for the year were 25.2%, with MacDermid delivering an adjusted EBITDA margin of 26.0%. These levels represent significant increases compared to the adjusted EBITDA margin of 24.1% reported in 2013.

Adjusted net income attributable to common shareholders rose to $113.6 million in 2014 from $89.6 million in 2013.

Adjusted diluted earnings per share were $0.59, compared to $0.46 per adjusted diluted earnings per share in 2013.

Adjusted recurring free cash flow of $148.2 million, or $0.77 per adjusted diluted share, was 51.4% higher in 2014 compared to the $97.9 million, or $0.51 per adjusted diluted share, reported in 2013.

Daniel H. Leever, Platform's Chief Executive Officer, commented, "Our remarkable performance in 2014 continued into the fourth quarter. MacDermid delivered record top- and bottom-line results and both CAS and Agriphar added meaningful contributions. Importantly, we achieved these results in spite of currency headwinds and increased investments back into the business. With the Arysta acquisition —our third and largest AgroSolutions acquisition— completed we have expanded our leadership capabilities and have already accelerated our integration plans. Based on our progress in integration and integration planning in just the past month, we are revising our projected three-year synergy target upwards from $65 million to $80 million."

In the fourth quarter of 2014, Platform closed its acquisitions of the Agriphar Group ("Agriphar") and Chemtura AgroSolutions ("CAS") and announced its acquisition of Arysta LifeScience ("Arysta"). The Company also completed several financings related to these transactions including a $650 million private placement of common shares, $402 million registered equity offering, and two term loan deals for an aggregate of approximately $700 million.

Wayne Hewett, Platform's President, noted, "While it's evident that Platform took significant strides to establish a meaningful presence in the agrochemicals space in 2014, it's important to underscore the quality of the assets that we have acquired. CAS, Agriphar, and Arysta all delivered record EBITDA levels in 2014 demonstrating the strength of these individual businesses. We believe that combining the three will yield a powerful offering in terms of product portfolio, crop exposure, and geographic reach that will help us accelerate growth and ultimately drive cash flow generation."

The Company has presented both US GAAP and adjusted financials to better provide investors with measures that allow them to more readily compare the performance of the Company. These adjusted amounts will provide investors insight into the cash generated from operations after taking into consideration reinvestment in the business for Free Cash Flow, Recurring Free Cash Flow, and Adjusted EBITDA.

Conference Call

Platform will host a webcast/dial-in conference call to discuss its fourth quarter and full year 2014 financial results at 8:00 a.m. (Eastern Time) on Wednesday, March 18, 2015. Participants on the call will include Daniel H. Leever, Chief Executive Officer, Wayne Hewett, President, and Frank J. Monteiro, Chief Financial Officer.

To listen to the call by telephone, please dial (855) 357-3116 (domestic) or (484) 365-2867 (international) and provide the Conference ID: 82833025. The call will be simultaneously webcast at www.platformspecialtyproducts.com. A replay of the call and webcast will be available for three weeks shortly after completion of the live call at www.platformspecialtyproducts.com.

About Platform

Platform is a global producer of high-technology specialty chemicals and provider of technical services. The business involves the manufacture of a broad range of specialty chemicals, created by blending raw materials, and the incorporation of these chemicals into multi-step technological processes. These specialty chemicals and processes are sold into multiple industries including agricultural, electronics, graphic arts, metal and plastic plating, and offshore oil production and drilling. More information on Platform is available at www.platformspecialtyproducts.com.

Forward-Looking Statements

This release is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 as it contains "forward-looking statements" within the meaning of the federal securities laws, which include statements regarding Platform's adjusted earnings per share, expected or estimated revenue, the outlook for Platform's markets and the demand for its products, estimated sales, segment earnings, net interest expense, income tax provision, restructuring and other charges, cash flows from operations, consistent profitable growth, free cash flow, future revenues and gross operating and adjusted EBITDA margin improvement requirement and expansion, organic net sales growth, bank debt covenants, the success of new product introductions, growth in costs and expenses, the impact of commodities and currencies and Platform's ability to manage its risk in these areas, and the impact of acquisitions, divestitures, restructuring and other unusual items, including Platform's ability to successfully complete as well as integrate and obtain the anticipated results and synergies from its consummated and future acquisitions. These projections and statements are based on management's estimates and assumptions with respect to future events and financial performance, and are believed to be reasonable, though are inherently difficult to predict. Actual results could differ materially from those projected as a result of certain factors. A discussion of factors that could cause results to vary is included in Platform's periodic and other reports filed with the Securities and Exchange Commission, including Platform's annual report on Form 10-K for the fiscal year ended December 31, 2013 and quarterly reports on Form 10-Q for the fiscal quarters ended June 30, 2014 and September 30, 2014. Platform undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

—FINANCIAL TABLES TO FOLLOW—

PLATFORM SPECIALTY PRODUCTS CORPORATION

CONSOLIDATED BALANCE SHEETS

($ In thousands)

December 31, 2014

December 31, 2013

Assets

Cash & cash equivalents

$ 397,280

$ 123,040

Restricted cash

599,946

--

Accounts receivable, net of allowance for doubtful accounts of $9,598 and $10,113 at December 31, 2014 and December 31, 2013, respectively

327,346

140,525

Inventories

205,843

89,618

Prepaid expenses & other current assets

47,954

30,269

Total current assets

1,578,369

383,452

Property, plant & equipment, net

174,958

136,166

Goodwill

1,405,294

989,808

Intangible assets, net

1,341,480

720,302

Other assets

57,420

30,426

Total assets

4,557,521

2,260,154

Liabilities & Stockholders' Equity

Accounts payable

106,671

56,156

Accrued salaries, wages and employee benefits

31,319

22,656

Current portion of long-term debt

15,071

7,958

Accrued income taxes payable

16,668

6,669

Accrued acquisition payable

14,278

--

Accrued expenses and other current liabilities

58,596

26,234

Total current liabilities

242,603

119,673

Long-term debt

1,400,823

744,291

Long-term deferred income taxes

202,292

169,800

Long term contingent consideration

63,900

34,800

Long term retirement plans

38,845

25,129

Other long-term liabilities

56,460

30,387

Total liabilities

2,004,923

1,124,080

Commitments and contingencies

Redeemable 401(k) plan interest

--

20,972

--

--

Stockholders' Equity

Preferred shares (2,000,000 designated as Series A), 5,000,000 shares authorized at December 31, 2014 and December 31, 2013, respectively; 2,000,000 shares issued and outstanding at December 31, 2014 and December 31, 2013

20

--

Common shares, 400,000,000 shares authorized, 182,066,980 and 103,571,941 shares issued and outstanding at December 31, 2014 and 2013, respectively

g Adjustment to reverse net mark-to-market gain on foreign exchange forward contracts entered into to finance Chemtura and Agriphar Acquisitions in Q4 2014. Adjustment to eliminate gain on sale of building in Q4 2013.

h Adjustment to calculation of estimated effective tax rate of 36% in Q4 2014 and 36% in Q4 2013.

i Adjustment for reversal of the income attributable to the non-controlling interest resulting from the MacDermid Acquisition.

j Reversal of accrued stock dividend to Founders issued in January 2015.

k Reversal of accrued accretion on Predecessor preferred stock dividends that were not paid until the MacDermid Acquisition.

l Weighted average basic shares for Q4 2014 are being used for Q4 2013 for comparison.

Conversion of exchange rights held by selling stockholders of MacDermid

8,641

Common shares equivalent of founder's preferred shares

2,000

Vested Director stock options

250

Equity awards granted in 2014

142

Adjusted Diluted shares at December 31, 2014

193,100

(1) For the quarter ended December 31, 2013, adjustments to net income included combining predecessor (MacDermid) results for the period from October 1, 2013 through October 31, 2013 with the Company's results as Platform did not own MacDermid for any of the predecessor period or for the entirety of the successor period. The successor period reflects Platform's new accounting basis as of the MacDermid acquisition and combined results are presented for comparative purposes.

PLATFORM SPECIALTY PRODUCTS CORPORATION

NON-GAAP AS ADJUSTED INCOME STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2014 AND 2013

(In thousands, except per share amounts)

Year Ended December 31, 2014

Adjustments 2014

As Adjusted Year Ended December 31, 2014

Combined (1)Year Ended December 31, 2013

Adjustments 2013

As Adjusted Year Ended December 31, 2013

Successor

Successor

Net sales

$ 843,186

$ --

$ 843,186

$ 745,951

$ --

$ 745,951

Cost of sales

446,633

(35,514)

a

411,119

387,463

(24,192)

363,271

Gross profit

396,553

35,514

432,067

358,488

24,192

382,680

Operating expenses:

Selling, technical, general and administrative

357,872

(145,372)

b,c,d

212,500

262,076

(69,602)

c

192,474

Non-cash charge related to preferred stock dividend rights

--

--

--

172,006

(172,006)

e

Research and development

26,229

--

26,229

23,893

(290)

23,603

Restructuring

2,955

(2,955)

--

4,398

(4,398)

--

Total operating expenses

387,056

(148,327)

238,729

462,373

(246,296)

216,077

Operating profit (loss)

9,497

183,841

193,338

(103,885)

270,488

166,603

Other income (expense):

Interest, net

(37,902)

--

(37,902)

(51,300)

21,031

f

(30,269)

Loss on extinguishment of debt

--

--

--

(18,788)

18,788

g

--

Other (expense) income

(2,484)

842

h

(1,642)

(996)

(1,143)

h

(2,139)

(40,386)

842

(39,544)

(71,084)

38,676

(32,408)

(Loss) income before income taxes, non-controlling interests and dividends on preferred shares

Conversion of exchange rights held by selling stockholders of MacDermid

8,641

Common shares equivalent of founder's preferred shares

2,000

Vested Director stock options

250

Equity awards granted in 2014

142

Adjusted Diluted shares at December 31, 2014

193,100

(1) For the year ended December 31, 2013, adjustments to net income included combining predecessor (MacDermid) results for the period from January 1, 2013 through October 31, 2013 with the Company's results as Platform did not own MacDermid for any of the predecessor period or for the entirety of the successor period. The successor period reflects Platform's new accounting basis as of the MacDermid acquisition and combined results are presented for comparative purposes.

PLATFORM SPECIALTY PRODUCTS CORPORATION

RECONCILIATION OF NON-GAAP MEASURES

Includes Predecessor and Successor data

Combined

Successor

Combined

Successor

(in millions)

Q4 2013

Q4 2014

YTD 2013

YTD 2014

Net loss

$ (200.1)

$ (34.0)

$ (181.0)

$ (29.9)

Adjustments to reconcile to net loss:

Income tax (benefit) expense

(13.8)

(3.1)

7.1

(6.7)

Interest expense

10.8

14.9

51.8

38.7

Depreciation and amortization expense

16.2

30.7

45.6

88.0

(1)

Equity based compensation expense

9.6

0.5

9.6

1.3

(2)

Restructuring and related expenses

2.5

2.0

8.0

3.0

(3)

Non cash charges related to Founder Preferred Dividend

172.0

--

172.0

--

(4)

Predecessor loss on extinguishment of debt

--

--

18.8

--

(5)

Manufacturer's profit in inventory adjustment

23.9

23.6

23.9

35.5

(6)

Non-cash fair value adjustment to contingent consideration

--

3.0

--

29.1

(7)

Acquisition Costs

32.1

29.5

32.1

47.8

(8)

Other expense (income)

(8.7)

(1.4)

(7.8)

5.4

(9)

Adjusted EBITDA

$ 44.5

$ 65.7

$ 180.1

$ 212.2

Footnotes:

(1) Includes $23.8 million in Q4 2014 and $11.1 million in Q4 2013 and $67.4 million in YTD 2014 and $31.3 million in YTD 2013 for amortization expense that is added back in the "As Adjusted" Income Statement.

(2) Adjustment for predecessor stock compensation and long term incentive plan expense.

(3) Includes restructuring expenses of $1.9 million of reorganization costs adjusted out of operating expenses for YTD 2013.

(4) Non-cash charge related to preferred stock dividend rights.

(5) Adjustment to eliminate extinguishment of debt associated with recapitalization of MacDermid in Q2 2013.

(7) Adjustment to fair value of contingent consideration in connection with the MacDermid Acquisition primarily associated with achieving the share price targets.

(8) Adjustment to reverse deal costs primarily in connection with the MacDermid Acquisition for YTD 2013 and the Chemtura, Arysta and Agriphar Acquisitions for YTD 2014.

(9) Adjustment for 2014 primarily for reversal of the income attributable to the non-controlling interest resulting from the MacDermid Acquisition. For 2013, adjustment to reverse miscellaneous non-recurring charges.